This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Weinong Guo, M.D., Ph.D.
Senior Vice President, Clinical Development at Alnylam Pharmaceuticals

Profile

Dr. Weinong Guo Joined Alnylam in May 2021 and is currently Senior Vice President of Clinical Research. In this role, he leads the Clinical Research team and oversees the clinical development programs in CardioMetabolic and Prevalent Disease area, including Zilebesiran (formerly known as ALN-AGT), Lumasiran, ALN-HSD, and ALN-XDH, etc. Before joining Alnylam, he worked in CardioRenalMetabolic Development Unit in Novartis for about 14 years where he played a key role in a number of high-priority clinical development programs including successful registration and life cycle management of EntrestoÒ (sacubitril/valsartan) for chronic heart failure, hypertension and myocardial infarction. Dr. Guo spent 20 years in the industry including Solvay and Schering-Plough during his early career. Dr. Guo received his MD degree from Soochow University in China and his PhD from Nagoya University in Japan. He completed his cardiology training at 2nd Affiliated Hospital at Soochow University, and an AHA postdoctoral fellowship in cardiac electrophysiology and pharmacology at Washington University in St. Louis before joining the industry. He has been a Fellow of American College of Cardiology since 2005

Agenda Sessions

  • RNAi Therapeutics for Cardiometabolic Disease: the Start of a New Age

    4:15pm